The Pivotal Role of Copper in Neurodegeneration: A New Strategy for the Therapy of Neurodegenerative Disorders

Molecular Pharmaceutics

Volumn 15, Issue 3, 2018, Pages 808-820

  Giampietro, Roberta ^a   Spinelli, Francesco ^a   Contino, Marialessandra ^a   Colabufo, Nicola Antonio ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

copper; metal chelators; natural compounds; neurodegenerative diseases; oxidative stress

Indexed keywords

CHELATING AGENT; COPPER; COPPER CHELATING AGENT; CURCUMIN; CURCUMIN DERIVATIVE; FLAVONOID; RESVERATROL; RESVERATROL DERIVATIVE; UNCLASSIFIED DRUG; COPPER EXPORTING ADENOSINE TRIPHOSPHATASE; COPPER ZINC SUPEROXIDE DISMUTASE; SOD1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; HUMAN; MENKES SYNDROME; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; WILSON DISEASE; ANIMAL; BRAIN CHEMISTRY; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; BRAIN CHEMISTRY; CHELATING AGENTS; COPPER; COPPER-TRANSPORTING ATPASES; DISEASE MODELS, ANIMAL; HUMANS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE-1;

EID: 85043261614     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.7b00841     Document Type: Review

References (90)

1. Angelova, M.; Asenova, S.; Nedkova, V.; Koleva, K. R. Copper in the human organism. Trakia J. Sci. 2011, 9, 88-98
2. Capo, C. R.; Arciello, M.; Squitti, R.; Cassetta, E.; Rossini, P. M.; Calabrese, L.; Rossi, L. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. BioMetals 2008, 21, 367-372
3. Nischwitz, V.; Berthele, A.; Michalke, B. Speciation analysis of selected metals and determination of their total contents in paired serum and cerebrospinal fluid samples: an approach to investigate the permeability of the human blood-cerebrospinal fluid-barrier. Anal. Chim. Acta 2008, 627, 258-269
4. Madsen, E.; Gitlin, J. D. Copper and iron disorders of the brain. Annu. Rev. Neurosci. 2007, 30, 317-337
5. Opazo, C. M.; Greenough, M. A.; Bush, A. I. Copper: from neurotransmission to neuroproteostasis. Front. Aging Neurosci. 2014, 6, 1-7
6. Gaier, E. D.; Eipper, B. A.; Mains, R. E. Copper signalling in the mammalian nervous system: synaptic effects. J. Neurosci. Res. 2013, 91, 2-19
7. Scheiber, I. F.; Mercer, J. F. B.; Dringen, R. Metabolism and functions of copper in brain. Prog. Neurobiol. 2014, 116, 33-57
8. Ahuja, A.; Dev, K.; Tanwar, R. S.; Selwal, K. K.; Tyagi, P. K. Copper mediated neurological disorder: visions into amyotrophic lateral sclerosis, Alzheimer and Menkes disease. J. Trace Elem. Med. Biol. 2015, 29, 11-23
9. D'Ambrosi, N.; Rossi, L. Copper at synapse: release, binding and modulation of neurotransmission. Neurochem. Int. 2015, 90, 36-45
10. Gil-Bea, F. J.; Aldanondo, G.; Lasa-Fernandez, H.; Lopez Munain, A.; Vallejo-Illarramendi, A. Insights into the mechanisms of copper dyshomeostasis in amyotrophic lateral sclerosis. Expert Rev. Mol. Med. 2017, 19, 1-14
11. Scheiber, I. F.; Bruha, R.; Dusek, P. Pathogenesis of Wilson disease. Handb. Clin. Neurol. 2017, 142, 43-50
12. Bandmann, O.; Weiss, K. H.; Kaler, S. G. Wilson's disease and other neurological copper disorders. Lancet Neurol. 2015, 14, 103-113
13. Helman, N. E.; Gitilin, J. D. Ceruloplasmin metabolism and function. Annu. Rev. Nutr. 2002, 22, 439-458
14. Lorincz, M. T. Neurologic Wilson's disease. Ann. N. Y. Acad. Sci. 2010, 1184, 173-187
15. Bandmann, O.; Weiss, K. H.; Kaler, S. G. Wilson's disease and other neurological copper disorders. Lancet Neurol. 2015, 14, 103-113
16. Brewer, G. J. The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease. J. Trace Elem. Med. Biol. 2014, 28, 372-378
17. A phase 2, multi-centre, open-label, study to evaluate the efficacy and safety of WTX101 administered for 24 weeks in newly diagnosed Wilson disease patients aged 18 and older with an extension phase of 12 months; https://clinicaltrials.gov/ct2/show/NCT02273596
18. Weiss, K. H.; Askari, F. K.; Czlonkowska, A.; Ferenci, P.; Bronstein, J. M.; Bega, D.; Ala, A.; Nicholl, D.; Flint, S.; Olsson, L.; Plitz, T.; Bjartmar, C.; Schilsky, M. L. Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study. Lancet. Gastroenterol. Hepatol. 2017, 2, 869-876
19. Kaler, S. G. ATP7A-related copper transport diseases-Emerging concepts and future trends. Nat. Rev. Neurol. 2011, 7, 15-29
20. Tumer, Z.; Møller, L. B.; Horn, N. Mutation Spectrum of ATP7A, the Gene Defective in Menkes Disease. In Copper Transport and Its Disorders: Molecular and Cellular Aspects; Leone, A., Mercer, J. F. B., Eds.; Springer US: Boston, MA, 1999; pp 83-95
21. Bhattacharjee, A.; Yang, H.; Duffy, M.; Robinson, E.; Conrad-Antoville, A.; Lu, Y. W.; Capps, T.; Braiterman, L.; Wolfgang, M.; Murphy, M. P.; Yi, L.; Kaler, S. G.; Lutsenko, S.; Ralle, M. The activity of Menkes disease protein ATP7A is essential for redox balance in mitochondria. J. Biol. Chem. 2016, 291, 16644-16658
22. Liu, P. C.; Chen, Y. W.; Centeno, J. A.; Quezado, M.; Lem, K.; Kaler, S. G. Downregulation of myelination, energy and translational genes in Menkes disease brain. Mol. Genet. Metab. 2005, 85, 291-300
23. Early copper histidine therapy in Menkes disease; http:// clinicaltrials.gov/ct2/show/NCT00001262
24. Molecular bases of response to copper treatment in Menkes disease, related phenotypes, and unexplained copper deficiency; https://clinicaltrials.gov/ct2/show/NCT00811785
25. Kaler, S. G. Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment. J. Trace Elem. Med. Biol. 2014, 28, 427-430
26. Santos, M. A.; Chand, K.; Chaves, S. Recent progress in multifunctional metal chelators as potential drugs for Alzheimer's disease. Coord. Chem. Rev. 2016, 327-328, 287-303
27. Gu, L.; Tran, J.; Jiang, L.; Guo, Z. A new structural model of Alzheimer's AB42 fibrils based on electron paramagnetic resonance data and Rosetta modelling. J. Struct. Biol. 2016, 194, 61-67
28. Singh, I.; Sagare, A. P.; Coma, M.; Perlmutter, D.; Gelein, R.; Bell, R. D.; Deane, R. J.; Zhong, E.; Parisi, M.; Ciszewski, J.; Kasper, R. T.; Deane, R. Low levels of copper disrupt brain amyloid-B homeostasis by altering its production and clearance. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 14771-14776
29. Atwood, C. S.; Perry, G.; Zeng, H.; Kato, J.; Jones, W. D.; Ling, K. Q.; Huang, X.; Moir, R. D.; Wang, D.; Sayre, L. M.; Smith, M. A.; Chen, S. G.; Bush, A. I. Copper mediates dityrosine cross-linking of Alzheimer's amyloid beta. Biochemistry 2004, 43, 560-568
30. Cheignon, C.; Tomas, M.; Bonnefont-Rousselot, D.; Faller, P.; Hureau, C.; Collin, F. Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 2018, 14, 450-464
31. Cherny, R. A.; Atwood, C. S.; Xilinas, M. E.; Gray, D. N.; Jones, W. D.; McLean, C. A.; Barnham, K. J.; Volitakis, I.; Fraser, F. W.; Kim, Y.; Huang, X.; Goldstein, L. E.; Moir, R. D.; Lim, J. T.; Beyreuther, K.; Zheng, H.; Tanzi, R. E.; Masters, C. L.; Bush, A. I. Treatment with a copper-zinc chelator markedly and rapidly inhibits B-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30, 665-676
32. Faux, N. G.; Ritchie, C. W.; Gunn, A.; Rembach, A.; Tsatsanis, A.; Bedo, J.; Harrison, J.; Lannfelt, L.; Blennow, K.; Zetterberg, H.; Ingelsson, M.; Masters, C. L.; Tanzi, R. E.; Cummings, J. L.; Herd, C. M.; Bush, A. I. PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J. Alzheimer's Dis. 2010, 20, 509-516
33. Arbiser, J. L.; Kraeft, S. K.; van Leeuwen, R.; Hurwitz, S. J.; Selig, M.; Dickersin, G. R.; Flint, A.; Byers, H. R.; Chen, L. B. Clioquinolzinc chelate: a candidate causative agent of subacute myelo-optic neuropathy. Mol. Med. 1998, 4, 665-670
34. Takeda, A.; Takada, S.; Ando, M.; Itagaki, K.; Tamano, H.; Suzuki, M.; Iwaki, H.; Oku, N. Impairment of recognition memory and hippocampal long term potentiation after acute exposure to chloroquinol. Neuroscience 2010, 171, 443-450
35. http : / / w w w . p r n e w s w i r e. c om/ n e w s-r e l e a s e s / pranabiotechnology-announces-preliminary-results-of-phase-2-imagine-trialof-pbt2-in-alzheimers-disease-253173581.html
36. Cui, Z.; Lockman, P. R.; Atwood, C. S.; Hsu, C.-H.; Gupte, A.; Allen, D. D.; Mumper, R. J. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharm. Biopharm. 2005, 59, 263-272
37. Okita, Y.; Rcom-Gauthier, A. N.; Goulding, M.; Chung, R. S.; Faller, P.; Pountney, D. L. Metallothionein, copper and alphasynuclein in alpha-synucleoinopathies. Front. Neurosci. 2017, 11, 114
38. Nussbaum, R. L. Genetics of synucleinophaties. Cold Spring Harbor Perspect. Med. 2017, a024109
39. Wirdefeldt, K.; Adami, H.; Cole, P.; Trichopoulos, D.; Mandel, J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 2011, 26, 1
40. Dell'Acqua, S.; Pirota, V.; Anzani, C.; Rocco, M. M.; Nicolis, S.; Valensin, D.; Monzani, E.; Casella, L. Reactivity of copper-A-synuclein peptide complexes relevant to Parkinson's disease. Metallomics 2015, 7, 1091-1102
41. Carboni, E.; Lingor, P. Insights on the interaction of alphasynuclein and metals in the pathophysiology of Parkinson's disease. Metallomics 2015, 7, 395-404
42. Villar-Pique, A.; Rossetti, G.; Ventura, S.; Carloni, P.; Fernandez, C. O.; Outeiro, T. F. Copper(II) and the pathological H50Q a-synuclein mutant: environment meets genetics. Commun. Integr. Biol. 2017, 10, e1270484
43. Wilkins, S.; Masters, C. L.; Bush, A. I.; Cherny, R. A.; Finkelstein, D. I. Clioquinol protects against cell death in Parkinson's disease models in vivo and in vitro. In The Basal Ganglia IX; Groenewegen, H. J., Voorn, P., Berendse, H. W., Mulder, A. B., Cools, A. R., Eds.; Springer New York: New York, NY, 2009; pp 431-442
44. Davies, K. M.; Mercer, J. F. B.; Chen, N.; Double, K. J. Copper dyshomeostasis in Parkinson's disease: implication for pathogenesis and indications for novel therapeutics. Clin. Sci. 2016, 130, 565-574
45. Hung, L. W.; Villemagne, V. L.; Cheng, L.; Sherratt, N. A.; Ayton, S.; White, A. R.; Crouch, P. J.; Lim, S.; Leong, S. L.; Wilkins, S.; George, J.; Roberts, B. R.; Pham, C. L. L.; Liu, X.; Chiu, F. C. K.; Shackleford, D. M.; Powell, A. K.; Masters, C. L.; Bush, A. I.; O'Keefe, G.; Culvenor, J. G.; Cappai, R.; Cherny, R. A.; Donnelly, P. S.; Hill, A. F.; Finkelstein, D. I.; Barnham, K. J. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. J. Exp. Med. 2012, 209, 837-854
46. A phase 1 dose escalation study of Cu(II)ATSM administered orally to patients with early idiopathic Parkinson's disease; https:// clinicaltrials.gov/ct2/show/NCT03204929
47. Bourassa, M. W.; Brown, H. H.; Borchelt, D. R.; Vogt, S.; Miller, L. M. Metal-deficient aggregates and diminished copper found in cells expressing SOD1 mutations that cause ALS. Front. Aging Neurosci. 2014, 6, 110
48. Ellerby, L. M.; Cabelli, D. E.; Graden, J. A.; Valentine, J. S. Copper-zinc superoxide dismutase: why not pH-dependent? J. Am. Chem. Soc. 1996, 118, 6556-6561
49. Seetharaman, S. V.; Winkler, D. D.; Taylor, A. B.; Cao, X.; Whitson, L. J.; Doucette, P. A.; Valentine, J. S.; Schirf, V.; Demeler, B.; Carroll, M. C.; Culotta, V. C.; Hart, P. J. Disrupted zinc-binding sites in structures of pathogenic SOD1 variants D124V and H80R. Biochemistry 2010, 49, 5714-5725
50. Weihl, C. C.; Lopate, G. Motor neuron disease associated with copper deficiency. Muscle Nerve 2006, 34, 789-793
51. Chattopadhyay, M.; Valentine, J. S. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid. Redox Signaling 2009, 11, 1603-1614
52. Sirangelo, I.; Iannuzzi, C. The role of metal binding in the amyotrophic lateral sclerosis-related aggregation of copper-zinc superoxide dismutase. Molecules 2017, 22, 1429
53. Roberts, B. R.; Lim, N. K. J.; McAllum, E. J.; Donnelly, P. S.; Hare, D. J.; Doble, P. A.; Turner, B. J.; Price, K. A.; Lim, S. C.; Paterson, B. M.; Hickey, J. L.; Rhoads, T. W.; Williams, J. R.; Kanninen, K. M.; Hung, L. W.; Liddell, J. R.; Grubman, A.; Monty, J.-F.; Llanos, R. M.; Kramer, D. R.; Mercer, J. F. B.; Bush, A. I.; Masters, C. L.; Duce, J. A.; Li, Q. X.; Beckman, J. S.; Barnham, K. J.; White, A. R.; Crouch, P. J. Oral treatment with CuII(atsm) increases mutant SOD1 in vivo but protect motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2014, 34, 8021-8031
54. A phase 1 single and multiple dose escalation and pharmacokinetic study of Cu(II)ATSM administered orally to patients with amyotrophic lateral sclerosis/motor neuron disease; https:// clinicaltrials.gov/ct2/show/NCT02870634
55. A treatment continuation study for patients with amyotrophic lateral sclerosis/motor neuron disease who have successfully completed study CMD-2016-001; https://clinicaltrials.gov/ct2/ show/NCT03136809
56. Hottinger, A. F.; Fine, E. G.; Gurney, M. E.; Zurn, A. D.; Aebischer, P. The copper chelator D-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur. J. Neurosci. 1997, 9, 1548-1551
57. Tokuda, E.; Ono, S.; Ishige, K.; Watanabe, S.; Okawa, E.; Ito, Y.; Suzuki, T. Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp. Neurol. 2008, 213, 122-128
58. Robert, A.; Liu, Y.; Nguyen, M.; Meunier, B. Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer's disease. Acc. Chem. Res. 2015, 48, 1332-1339
59. Chan, S.; Kantham, S.; Rao, V. M.; Palanivelu, M. K.; Pham, H. J.; Shaw, P. N.; McGeary, R. P.; Ross, B. P. Metal chelation, radical scavenging and inhibition of AB42 fibrillation by food constituents in relation to Alzheimer's disease. Food Chem. 2016, 199, 185-194
60. Qiang, X.; Sang, Z.; Yuan, W.; Li, Y.; Liu, Q.; Bai, P.; Shi, Y.; Ang, W.; Tan, Z.; Deng, Y. Design, synthesis and evaluation of genistein-O-alkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 2014, 76, 314-331
61. Baum, L.; Ng, A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimer's Dis. 2004, 6, 367-369
62. Hamaguchi, T.; Ono, K.; Yamada, M. REVIEW: Curcumin and Alzheimer's disease. CNS Neurosci. Ther. 2010, 16, 285-297
63. Bhatia, N. K.; Srivastava, A.; Katyal, N.; Jain, N.; Khan, M. A. I.; Kundu, B.; Deep, S. Curcumin binds to the pre-fibrillar aggregates of Cu/Zn superoxide dismutase (SOD1) and alters its amyloidogenic pathway resulting in reduced cytotoxicity. Biochim. Biophys. Acta, Proteins Proteomics 2015, 1854, 426-436
64. Mazzanti, G.; Giacomo, S. Curcumin and resveratrol in the management of cognitive Disorders: what is the clinical evidence? Molecules 2016, 21, 1243
65. 18-Month double-blind, placebo-controlled study of curcumin; https://clinicaltrials.gov/ct2/show/NCT01383161
66. Curcumin and yoga exercise effects in veterans at risk for Alzheimer's disease; https://clinicaltrials.gov/ct2/show/ NCT01811381
67. Chen, S. Y.; Chen, Y.; Li, Y. P.; Chen, S. H.; Tan, J. H.; Ou, T. M.; Gu, L. Q.; Huang, Z. S. Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer's disease. Bioorg. Med. Chem. 2011, 19, 5596-5604
68. Saiko, P.; Szakmary, A.; Jaeger, W.; Szekeres, T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat. Res., Rev. Mutat. Res. 2008, 658, 68-94
69. Harikumar, K. B.; Aggarwal, B. B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7, 1020-1035
70. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discovery 2006, 5, 493-506
71. Tellone, E.; Galtieri, A.; Russo, A.; Giardina, B.; Ficarra, S. Resveratrol: a Focus on several neurodegenerative diseases. Oxid. Med. Cell. Longevity 2015, 2015, 392169
72. Turner, R. S.; Thomas, R. G.; Craft, S.; van Dyck, C. H.; Mintzer, J.; Reynolds, B. A.; Brewer, J. B.; Rissman, R. A.; Raman, R.; Aisen, P. S. A Randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology 2015, 85, 1383-1391
73. Randomized, placebo-controlled clinical trial of resveratrol supplement effects on cognition, function and behavior in patients with mild-to-moderate Alzheimer's disease; https://clinicaltrials.gov/ ct2/show/NCT00743743
74. A pilot study of resveratrol supplementation for memory and physical performance; https://clinicaltrials.gov/ct2/show/ NCT01126229
75. BDPP treatment for mild cognitive impairment (MCI) and prediabetes or type 2 diabetes mellitus (T2DM); https://clinicaltrials. gov/ct2/show/NCT02502253
76. Jang, J. H.; Surh, Y. J. Protective effect of resveratrol on betaamyloid-induced oxidative PC12 cell death. Free Radical Biol. Med. 2003, 34, 1100-1110
77. Narasimhulu, M.; Srikanth Reddy, K.; Chinni Mahesh, A.; Sai Krishna, J.; Venkateswara Rao, J.; Venkateswarlu, Y. Synthesis of yashanushidiol and its analogues and their cytotoxic activity against cancer cell lines. Bioorg. Med. Chem. Lett. 2009, 19, 3125-3127
78. Li, S. Y.; Wang, X. B.; Kong, L. Y. Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer's disease. Eur. J. Med. Chem. 2014, 71, 36-45
79. Colabufo, N. A.; Perrone, R.; Berardi, F.; Paradiso, A. Multidrug resistance: biological and pharmaceutical advances in antitumour treatment. Res. Signpost 2008, No. 4, 171-201
80. DeToma, A. S.; Choi, J. S.; Braymer, J. J.; Lim, M. H. Myricetin: a naturally occurring regulator of metal-induced amyloid-B aggregation and neurotoxicity. ChemBioChem 2011, 12, 1198-1201
81. Hyung, S. J.; Toma, A. S.; Brender, J. R.; Lee, S.; Vivekanandan, S.; Kochi, A.; Choi, J. S.; Ramamoorthy, A.; Ruotolo, B. T.; Lim, M. H. Insights into antiamyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate towards metal-associated amyloid-B species. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 3743-3748
82. Rufer, C. E.; Kulling, S. E. Antioxidant activity of isoflavones and their major metabolites using different in vitro assays. J. Agric. Food Chem. 2006, 54, 2926-2931
83. Bang, O. Y.; Hong, H. S.; Kim, D. H.; Kim, H.; Boo, J. Y.; Huh, K.; Mook-Jung, I. Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. Neurobiol. Dis. 2004, 16, 21-28
84. Li, S. Y.; Wang, X. B.; Xie, S. S.; Jiang, N.; Wang, K. D.; Yao, H. Q.; Sun, H. B.; Kong, L. Y. Multifunctional tacrine-flavonoid hybrids with cholinergic, B-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 2013, 69, 632-646
85. Ferrada, E.; Arancibia, V.; Loeb, B.; Norambuena, E.; Olea-Azar, C.; Huidobro-Toro, J. P. Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimer's and Huntington's disease therapy. NeuroToxicology 2007, 28, 445-449
86. Deraeve, C.; Boldron, C.; Maraval, A.; Mazarguil, H.; Gornitzka, H.; Vendier, L.; Pitie, M.; Meunier, B. Preparation and study of new poly-8-hydroxyquinoline chelators for anti-Alzheimer strategy. Chem.-Eur. J. 2008, 14, 682-696
87. Ceccom, J.; Cosledan, F.; Halley, H.; Frances, B.; Lassalle, J. M.; Meunier, B. Copper chelator induced efficient episodic memory recovery in a non-transgenic Alzheimer's mouse model. PLoS One 2012, 7, e43105
88. Li, X.; Wang, H.; Lu, Z.; Zheng, X.; Ni, W.; Zhu, J.; Fu, Y.; Lian, F.; Zhang, N.; Li, J.; Zhang, H.; Mao, F. Development of multifunctional pyrimidinylthiourea derivatives as potential anti-Alzheimer agents. J. Med. Chem. 2016, 59, 8326-8344
89. Quintanova, C.; Keri, R. S.; Chaves, S.; Santos, M. A. Copper(II) complexation of tacrine hybrids with potential antineurodegenerative roles. J. Inorg. Biochem. 2015, 151, 58-66
90. Cummings, J. L.; Morstorf, T.; Zhong, K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's Res. Ther. 2014, 6, 37